Maven Securities’s GenMark Diagnostics, Inc GNMK Stock Holding History

Maven Securities’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-80,000	Closed	-$947K	–	50
2017 Q2	$947K	Buy	+80,000	New	+$1.02M	0.65%	18

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Maven Securities's GNMK Position: Q3 2017 in Review

Maven Securities sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2017, closing a stake of 80,000 shares — an estimated $947K sold.

Maven Securities first reported a position in GNMK in Q2 2017 and held it in 1 quarter. The position peaked at $947K in Q2 2017. 96 funds tracked by Wall St. Rank hold GNMK as of Q3 2017.

Maven Securities reported no remaining GenMark Diagnostics, Inc position as of Q3 2017 after selling out during the quarter.
Maven Securities sold 80,000 GenMark Diagnostics, Inc shares in Q3 2017, an estimated $947K.
Maven Securities first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 1 quarter.
Maven Securities's GenMark Diagnostics, Inc position peaked at $947K in Q2 2017.
96 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2017.

Based on Maven Securities's 13F filing for Q3 2017, filed 14 Nov 2017.